Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Conivaptan Hydrochloride

FDA-approved product (injectable, intravenous), marketed as Vaprisol, Vaprisol In 5% Dextrose In Plastic Container.

Registered studies
21
Lab records
0
Pathogens at ≥40%
3 of 4

Chemical structure

Chemical structure of Conivaptan Hydrochloride
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Cardiovascular disease
  • Heart failure

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Vasopressin antagonists
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against MRSA, E. coli and M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA54.5% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli44.1% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae25.4% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis56.4% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

21registered studies name this medicine, for any condition. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Conivaptan Hydrochloride in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

Not yet docked: queued in the docking rundetails

KPC-2 carbapenemase ↗ (K. pneumoniae)

Not yet docked: queued in the docking rundetails

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

Not yet docked: queued in the docking rundetails

Dihydrofolate reductase ↗ (MRSA)

Not yet docked: queued in the docking rundetails

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Conivaptan Hydrochloride with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Study of Efficacy & Safety for 3 Infusion Regimens of IV Conivaptan in Subjects With Euvolemic or Hypervolemic Hyponatremia

    NCT00478192 · start 2007-04

    Registered record
    Registry ID
    NCT00478192
    Conditions
    Hyponatremia
    Interventions
    Conivaptan; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2007-04
    Completion
    2008-08
    Enrolment
    50

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHyponatremia
    InterventionConivaptan; Placebo
    PhasePhase 3
    Registry statusCompleted

  • A Study of Multiple Dosing Regimens of IV Conivaptan in Subjects With Euvolemic or Hypervolemic Hyponatremia

    NCT00435591 · start 2007-01

    Registered record
    Registry ID
    NCT00435591
    Conditions
    Hyponatremia; Euvolemia; Hypervolemia
    Interventions
    Conivaptan; placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2007-01
    Completion
    2008-09
    Enrolment
    121

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHyponatremia; Euvolemia; Hypervolemia
    InterventionConivaptan; placebo
    PhasePhase 4
    Registry statusCompleted

  • An Open-Label Study of YM087 (Conivaptan) in Patients With Euvolemic or Hypervolemic Hyponatremia

    NCT00379847 · start 2004-02

    Registered record
    Registry ID
    NCT00379847
    Conditions
    Hyponatremia
    Interventions
    conivaptan
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2004-02
    Completion
    2005-06
    Enrolment
    251

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHyponatremia
    Interventionconivaptan
    PhasePhase 3
    Registry statusCompleted

  • Safety and Efficacy Study of YM087 (Conivaptan) in Patients With Acute Decompensated Heart Failure

    NCT00057356 · start 2002-11

    Registered record
    Registry ID
    NCT00057356
    Conditions
    Chronic Heart Failure
    Interventions
    conivaptan; placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2002-11
    Completion
    2004-03
    Enrolment
    170

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionChronic Heart Failure
    Interventionconivaptan; placebo
    PhasePhase 2
    Registry statusCompleted

  • Study of IV YM087 to Assess Efficacy and Safety in Patients With Euvolemic or Hypervolemic Hyponatremia

    NCT00380575 · start 2000-08

    Registered record
    Registry ID
    NCT00380575
    Conditions
    Hyponatremia
    Interventions
    YM087
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2000-08
    Completion
    2003-02
    Enrolment
    84

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHyponatremia
    InterventionYM087
    PhasePhase 3
    Registry statusCompleted

  • Study of Efficacy & Safety of Oral YM087 in Subjects With Euvolemic or Hypervolemic Hyponatremia

    NCT00492037 · start 2000-01

    Registered record
    Registry ID
    NCT00492037
    Conditions
    Hyponatremia
    Interventions
    YM087 oral
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2000-01
    Completion
    2002-02
    Enrolment
    83

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHyponatremia
    InterventionYM087 oral
    PhasePhase 3
    Registry statusCompleted